Drugs / U87
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06614686 | Sep 2024 → Oct 2026 expected | nasopharyngeal carcinoma | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U87 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06614686 ↗ |
| Modality | Cell therapy | “U87 chimeric antigen receptor T-cell infusion.” NCT06614686 ↗ |